At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 155 enrolled
Drug / intervention
Octreotide capsulesdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Oral Octreolin™ in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs
In Brief
A Phase 3 clinical trial evaluating Octreotide capsules for Acromegaly. Completed, enrolled 155 participants across 36 sites in 13 countries.
Detailed Summary
MYCAPSSA™ (formerly Octreolin™) is a proprietary oral form of the approved injectable medical product octreotide used to treat acromegaly. This study will evaluate the efficacy and safety of MYCAPSSA™ treatment in patients with acromegaly.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcromegaly
CountriesGermany, Hungary, Italy, Lithuania, Mexico, Netherlands, Poland, Romania, Serbia, Slovakia, Slovenia, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 2011
Enrollment StartMar 2012
Primary CompletionMay 2014
TodayJul 2026
First PostedAug 9, 2011
Enrollment StartMar 1, 2012
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 14.9 years ago
Interventions
Octreotide capsulesdrug
Octreotide was provided in hard gelatin capsules.